Quidel Co. (NASDAQ:QDEL) Receives Consensus Recommendation of “Buy” from Analysts

Quidel Co. (NASDAQ:QDELGet Rating) has been assigned an average rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $143.50.

QDEL has been the topic of several analyst reports. TheStreet cut Quidel from a “b-” rating to a “c+” rating in a research note on Thursday, February 10th. StockNews.com downgraded Quidel from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Raymond James upgraded Quidel from an “outperform” rating to a “strong-buy” rating and lowered their price target for the stock from $155.00 to $130.00 in a research report on Tuesday, February 22nd.

In other news, Director Mary Lake Ph D. Polan sold 1,525 shares of the company’s stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $113.59, for a total value of $173,224.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Western Pacific Wealth Management LP bought a new stake in shares of Quidel in the 4th quarter valued at about $26,000. New Century Advisors LLC acquired a new position in Quidel during the 4th quarter valued at about $31,000. Exane Derivatives boosted its stake in Quidel by 4,883.3% in the 1st quarter. Exane Derivatives now owns 299 shares of the company’s stock worth $34,000 after purchasing an additional 293 shares in the last quarter. Emerald Advisers LLC acquired a new stake in shares of Quidel during the fourth quarter worth $40,000. Finally, Vestor Capital LLC purchased a new stake in shares of Quidel during the third quarter valued at $42,000. 92.89% of the stock is currently owned by institutional investors.

QDEL stock opened at $98.29 on Monday. The firm has a fifty day moving average price of $107.75 and a 200 day moving average price of $119.19. Quidel has a fifty-two week low of $88.37 and a fifty-two week high of $180.06. The firm has a market cap of $4.11 billion, a PE ratio of 4.15 and a beta of 0.02.

Quidel (NASDAQ:QDELGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported $11.66 EPS for the quarter, topping analysts’ consensus estimates of $9.17 by $2.49. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $865.05 million. Quidel had a net margin of 43.26% and a return on equity of 56.46%. The business’s revenue was up 167.0% on a year-over-year basis. During the same period last year, the company posted $4.27 EPS. As a group, research analysts anticipate that Quidel will post 16.34 EPS for the current fiscal year.

About Quidel (Get Rating)

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye.

Featured Stories

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.